News

March 13, 2019

Launch of Entecavir in Bulgaria

Pharmascience International Limited is proud to announce the launch of Entecavir, its first launch of its own private label in the EU pharmaceutical market! The Canadian and European teams managed to launch this first Pharmascience International generic medication in Bulgaria and placed it on the market prior to all its competitors.

 

In Bulgaria, Entecavir is indicated in the treatment of chronic hepatitis B virus (HBV) infection in adults with:

  • Compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
  • Decompensated liver disease

The product offers patients and doctors the opportunity to familiarize themselves with the Pharmascience brand which will set the ground for the upcoming launches in the upcoming months.

Pharmascience International Limited plans to focus on delivering high quality healthcare products to hospitals in Central and Eastern European regions. This would be done directly through its own brand, providing patients access to high quality products manufactured in Canada.

Pharmascience